DE60304037D1 - Pluripotenzdeterminierender faktor und deren anwendung - Google Patents

Pluripotenzdeterminierender faktor und deren anwendung

Info

Publication number
DE60304037D1
DE60304037D1 DE60304037T DE60304037T DE60304037D1 DE 60304037 D1 DE60304037 D1 DE 60304037D1 DE 60304037 T DE60304037 T DE 60304037T DE 60304037 T DE60304037 T DE 60304037T DE 60304037 D1 DE60304037 D1 DE 60304037D1
Authority
DE
Germany
Prior art keywords
maintain
pluripotency
factors
confer
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60304037T
Other languages
English (en)
Other versions
DE60304037T2 (de
Inventor
Ian Chambers
Gerard Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Edinburgh
Original Assignee
University of Edinburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Edinburgh filed Critical University of Edinburgh
Application granted granted Critical
Publication of DE60304037D1 publication Critical patent/DE60304037D1/de
Publication of DE60304037T2 publication Critical patent/DE60304037T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
DE60304037T 2002-01-30 2003-01-30 Pluripotenzdeterminierender faktor und deren anwendungen Expired - Lifetime DE60304037T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0202149.1A GB0202149D0 (en) 2002-01-30 2002-01-30 Pluripotency determining factors and uses thereof
GB0202149 2002-01-30
PCT/GB2003/000366 WO2003064463A2 (en) 2002-01-30 2003-01-30 Pluripotency determining factors and uses thereof

Publications (2)

Publication Number Publication Date
DE60304037D1 true DE60304037D1 (de) 2006-05-11
DE60304037T2 DE60304037T2 (de) 2006-11-09

Family

ID=9930054

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60320599T Expired - Lifetime DE60320599T2 (de) 2002-01-30 2003-01-30 Pluripotenzdeterminierende Faktoren und deren Anwendung
DE60304037T Expired - Lifetime DE60304037T2 (de) 2002-01-30 2003-01-30 Pluripotenzdeterminierender faktor und deren anwendungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60320599T Expired - Lifetime DE60320599T2 (de) 2002-01-30 2003-01-30 Pluripotenzdeterminierende Faktoren und deren Anwendung

Country Status (11)

Country Link
US (2) US7687266B2 (de)
EP (2) EP1698639B1 (de)
JP (1) JP2005536183A (de)
KR (1) KR20040093699A (de)
CN (1) CN1646562A (de)
AT (2) ATE393167T1 (de)
DE (2) DE60320599T2 (de)
DK (2) DK1698639T3 (de)
ES (1) ES2308616T3 (de)
GB (1) GB0202149D0 (de)
WO (1) WO2003064463A2 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4268169B2 (ja) * 2003-01-31 2009-05-27 伸弥 山中 胚性幹細胞の自己複製決定因子
WO2004072226A2 (en) * 2003-02-13 2004-08-26 Reprocell Inc. Marker for undifferentiated state of cell and composition and method for separation and preparation of stem cells
ITRM20030376A1 (it) 2003-07-31 2005-02-01 Univ Roma Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
US7682828B2 (en) * 2003-11-26 2010-03-23 Whitehead Institute For Biomedical Research Methods for reprogramming somatic cells
WO2006025802A1 (en) * 2004-09-03 2006-03-09 Agency For Science, Technology And Research Method for maintaining pluripotency of stem/progenitor cells
US8192988B2 (en) * 2004-10-22 2012-06-05 University Of Central Florida Research Foundation, Inc. Methods for increasing potency of adult mesenchymal stem cells
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
US8759090B2 (en) * 2006-10-30 2014-06-24 University Of Central Florida Research Foundation, Inc. Stem cell banking system
GB0701062D0 (en) * 2007-01-19 2007-02-28 Evocell Ltd Biological materials and uses thereof
SG193653A1 (en) 2007-03-23 2013-10-30 Wisconsin Alumni Res Found Somatic cell reprogramming
EP2145000A4 (de) 2007-04-07 2010-05-05 Whitehead Biomedical Inst Neuprogammierung von körperzellen
WO2009032456A2 (en) * 2007-08-01 2009-03-12 Primegen Biotech Llc Non-viral delivery of transcription factors that reprogram human somatic cells into a stem cell-like state
US7615374B2 (en) 2007-09-25 2009-11-10 Wisconsin Alumni Research Foundation Generation of clonal mesenchymal progenitors and mesenchymal stem cell lines under serum-free conditions
ES2587395T3 (es) 2008-06-04 2016-10-24 Cellular Dynamics International, Inc. Procedimientos para la producción de células IPS usando un enfoque no vírico
CN105671065A (zh) 2008-06-13 2016-06-15 怀特黑德生物医学研究所 细胞编程和重编程
JP2012500005A (ja) 2008-08-12 2012-01-05 セルラー ダイナミクス インターナショナル， インコーポレイテッド ｉＰＳ細胞を生成するための方法
WO2011094538A1 (en) * 2010-01-29 2011-08-04 The Board Of Trustees Of The Leland Stanford Junior University Depletion of teratoma-forming pluripotent stem cells
US9845457B2 (en) 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
US9249392B2 (en) 2010-04-30 2016-02-02 Cedars-Sinai Medical Center Methods and compositions for maintaining genomic stability in cultured stem cells
WO2013086008A1 (en) 2011-12-05 2013-06-13 Factor Bioscience Inc. Methods and products for transfecting cells
US8497124B2 (en) 2011-12-05 2013-07-30 Factor Bioscience Inc. Methods and products for reprogramming cells to a less differentiated state
US9884076B2 (en) 2012-06-05 2018-02-06 Capricor, Inc. Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy
EP3563859B1 (de) 2012-08-13 2021-10-13 Cedars-Sinai Medical Center Von kardiosphären abgeleitete exosomen zur geweberegeneration
EP3786298A1 (de) 2012-11-01 2021-03-03 Factor Bioscience Inc. Verfahren und produkte zur expression von proteinen in zellen
CN103609526B (zh) * 2013-10-16 2015-10-07 中国科学院生物物理研究所 线粒体蛋白质翻译因子Guf1在雄性不育研究中的应用
EP3099801B1 (de) 2014-01-31 2020-03-18 Factor Bioscience Inc. Synthetische rna zur verwendung in der behandlung von epidermolysis bullosa dystrophica
WO2016054591A1 (en) 2014-10-03 2016-04-07 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
US11241505B2 (en) 2015-02-13 2022-02-08 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
WO2017123662A1 (en) 2016-01-11 2017-07-20 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
WO2017210652A1 (en) 2016-06-03 2017-12-07 Cedars-Sinai Medical Center Cdc-derived exosomes for treatment of ventricular tachyarrythmias
CA3033788A1 (en) 2016-08-17 2018-02-22 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
WO2018057542A1 (en) 2016-09-20 2018-03-29 Cedars-Sinai Medical Center Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
EP3612191A4 (de) 2017-04-19 2020-12-30 Cedars-Sinai Medical Center Verfahren und zusammensetzungen zur behandlung von skelettmuskeldystrophie
EP3727351A4 (de) 2017-12-20 2021-10-06 Cedars-Sinai Medical Center Manipulierte extrazelluläre vesikel für verbesserte freisetzung in gewebe
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996022693A1 (en) 1995-01-24 1996-08-01 The Board Of Regents Of The University Of Texas System Self-renewing pluripotent hematopoietic stem cell compositions, methods of use, and culture systems therefor
WO1997030151A1 (en) 1996-02-16 1997-08-21 The University Of Edinburgh Cytokine expressed by dia/lif-deficient embryonic stem cells for the inhibition of differentiation
US6159950A (en) * 1998-10-16 2000-12-12 Cornell Research Foundation, Inc. Method of modulating hair growth
US7005252B1 (en) 2000-03-09 2006-02-28 Wisconsin Alumni Research Foundation Serum free cultivation of primate embryonic stem cells
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
EP1402256A4 (de) * 2001-05-31 2006-09-13 Chiron Corp P-cadherin als ziel einer antikrebstherapie

Also Published As

Publication number Publication date
WO2003064463B1 (en) 2004-02-12
JP2005536183A (ja) 2005-12-02
ATE393167T1 (de) 2008-05-15
DK1698639T3 (da) 2008-07-14
US20050255573A1 (en) 2005-11-17
EP1470155A2 (de) 2004-10-27
WO2003064463A3 (en) 2003-12-11
US7687266B2 (en) 2010-03-30
EP1698639B1 (de) 2008-04-23
DE60304037T2 (de) 2006-11-09
WO2003064463A2 (en) 2003-08-07
ATE320446T1 (de) 2006-04-15
DE60320599T2 (de) 2009-10-29
DE60320599D1 (de) 2008-06-05
DK1470155T3 (da) 2006-07-24
GB0202149D0 (en) 2002-03-20
EP1470155B1 (de) 2006-03-15
US20100144039A1 (en) 2010-06-10
KR20040093699A (ko) 2004-11-08
EP1698639A3 (de) 2006-12-06
EP1698639A2 (de) 2006-09-06
ES2308616T3 (es) 2008-12-01
CN1646562A (zh) 2005-07-27

Similar Documents

Publication Publication Date Title
ATE320446T1 (de) Pluripotenzdeterminierender faktor und deren anwendung
ATE514772T1 (de) Multipotente erwachsene stammzellen und verfahren zu deren isolierung
IL238490A0 (en) Preparations and methods for regulating NK cell activity
BR0308919A (pt) Células-tronco programáveis, desdiferenciadas de origem monocìtica, e sua produção e uso
BR112014017158A8 (pt) aberturas tratadas
MXPA04000982A (es) Metodos para movilizar celulas progenitoras/madre.
ATE439429T1 (de) Multipotente neurale stammzellen aus hautgewebe und deren verwendungen
NZ612132A (en) Immunomodulation using placental stem cells
DE60135498D1 (de) Produktion von ganzen Antikörpern in prokaryontischen Zellen
BRPI0507118A (pt) polipeptìdeos de interferon humano modificado e seus usos
NZ596022A (en) Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
ATE323151T1 (de) Ex-vivo isolierte cd25+cd4+ t zellen mit immunsuppressiver aktivität und deren anwendungen
TW200704105A (en) User authentication using personal objects
BRPI0620291B8 (pt) método e uso de 4,4'-diaminodifenil sulfona para produzir cepas rugosas de bactérias e composição de modulador imune
BRPI0605942A (pt) composição cosmética para o tratamento de fibras de queratina, dispositivo em aerossol, processo de tratamento cosmético, e, uso de uma composição cosmética
WO2006094550A8 (de) Verwendung kosmetischer zubereitungen mit einem gehalt an nicht molekular gebundenem freien sauerstoff
ATE390059T1 (de) Vorrichtung, zum aufbewahren und auftragen bestehend aus einem aus partikeln bestehenden körper
DE60313580D1 (de) Persönliches pflegeprodukt
ATE363890T1 (de) Kationische polymerisate und deren verwendung in kosmetischen formulierungen
ATE434940T1 (de) Verfahren zur verbesserung der immunfunktion bei säugern unter verwendung von lactobacillus reuteri-stämmen
BR112012014730A2 (pt) "método cosmético para tratar odores corporais usando uma composição com base em bacteriocina"
ATE340253T1 (de) Zellkonstrukte erhältlich aus mesenchymalen stammzellen und davon ableitbaren zellen und ihre verwendung
WO2007005787A3 (en) Methods and compositions for keratinocyte culture and therapeutics
ATE365774T1 (de) Anorganische lichtabsorbierende mikropigmente und deren verwendung
WO2006040615A3 (en) Differenciation of stem cells for therapeutic use

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURG

8364 No opposition during term of opposition